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ABSTRACT
Objective: HIV mutation accumulation has great implica-
tions for pharmacoeconomics and clinical care, yet scarcity
of data has hindered its representation in decision analytic
models. Our objective is to determine the accuracy with
which mutation accumulation and other unmeasured param-
eters could be estimated during model calibration.
Methods: We used a second-order Monte Carlo simulation
of HIV natural history that had been calibrated by varying
two unmeasured parameters (mutation accrual rate and
probability of adherence) to minimize differences between
estimated and observed clinical outcomes (time to treatment
failure and survival). We compared these estimated values
ﬁrst with only those results that had been already published
at the time of model calibration, and second including results
that were published after model calibration.
Results: The value for mutation accrual rate assigned during
calibration was 0.014 mutations per month for antiretroviral
naive patients, at the lower bound of the results for nine
heterogeneous studies published at the time of calibration
(pooled 95% conﬁdence interval [CI] 0.014–0.039 mutations
per month). In contrast, this estimate accurately anticipated
results from 11 larger and more homogeneous studies pub-
lished after calibration (pooled 95% CI for antiretroviral
naïve patients, 0.012–0.015 mutations per month). The value
for probability of adherence assigned during calibration
(75%) was also within the range of published results (pooled
95% CI 62–76%).
Conclusion: Estimates for unobserved parameters derived
during model calibration were not only within the range of
clinical observations, but anticipated with accuracy clinical
results that were not yet available. It may be feasible to use
models to estimate unobserved parameters.
Keywords: adherence, genotypic resistance, HIV, antiretro-
viral therapy.
Introduction
The rate at which mutations accrue in the HIV genome
has great implications for the management of individu-
als with HIV because it impacts the effectiveness and
pharmacoeconomics of combination antiretroviral
therapies (CART). Resistance mutations attenuate
plasma HIV suppression by CART [1], which leads to
higher mortality from HIV-related causes [2,3], varia-
tions in the cost-effectiveness of CART [4], and may
result in different treatment strategies being preferred
[5]. Therefore, models used to predict clinical and
economic outcomes for a given treatment strategy are
likely to be more accurate if they include the accumu-
lation of resistance mutations as an explicit construct.
Despite the importance of characterizing mutation
accumulation, few studies have analyzed this outcome
prospectively, nor have clinical and policy models of
HIV disease incorporated this important attribute
explicitly [4,6–10]. Until recently, data describing the
accrual of resistance mutations have mostly originated
from small studies with variable results [11–19], and
this heterogeneity has been difﬁcult to attribute solely
to known differences among the sampled populations.
Our efforts to parameterize our simulation of HIV
natural history [5,20–22] were therefore hindered by
uncertainty. As a consequence, we assigned estimates
for the rate of mutation accumulation by choosing the
value that minimized the difference between expected
and observed results during its calibration.
Similar challenges in the modeling of disease
natural history have been faced by investigators devel-
oping cost-effectiveness models in other domains.
Researchers modeling cervical cancer and breast
cancer detection strategies have employed natural
history models that included preclinical stages of
cancer that are not routinely detected or characterized
in clinical populations [23–26]. Because these investi-
gators were unable to estimate these parameters solely
from clinical observations, they also needed to assign
Address correspondence to: R. Scott Braithwaite, Assistant
Professor, General Internal Medicine, Yale University School of
Medicine, VA CT Healthcare System—11ACSLG, 950 Camp-
bell Avenue, West Haven, CT 06516, USA. E-mail:
Ronald.braithwaite@med.va.gov
10.1111/j.1524-4733.2007.00170.x
Volume 10 • Number 3 • 2007
V A L U E I N H E A LT H
204 © 2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/07/204 204–213
estimates for their values based on model calibration.
Researchers optimizing ways to allocate livers for
transplantation have pursued a similar strategy [27].
Nevertheless, despite the increasing use of this
approach, there is no direct evidence that the estima-
tion of unobserved parameters during model calibra-
tion can produce accurate parameter estimates.
Soon after we estimated values for mutation rate
parameters in our HIV simulation, several studies were
published, which prospectively measured these param-
eters in large clinical populations, focusing exclusively
on populations similar to that which we were model-
ing [28–31]. We were therefore unwitting participants
in a “natural experiment” that enabled us to compare
our assigned estimates with observations from similar
populations. In this report, we use the natural experi-
ment to address the question of how our assigned
estimates compared with results that were published
subsequently, as well as to address the more general
question of whether it is feasible to use a natural
history model to estimate the value of an unobserved
parameter.
Methods
We ﬁrst describe our HIV model and its parameters,
then how we used calibration of the model to estimate
the value of the parameters that were unknown, and
ﬁnally how we compared our estimated results with
published results. The two parameters we estimated
during calibration were the mutation accumulation
rate and the level of adherence with antiretroviral
therapy. Calibration was performed using the same
data set that was used to estimate many important
parameters in the model [21].
Model Overview
We have created a second-order Monte Carlo simula-
tion that explicitly represents two of the processes that
undermine antiretroviral effectiveness in HIV disease:
development of genotypic resistance, and nonadher-
ence to medications [5,20,21,32]. These processes
inﬂuence the effectiveness of antiretroviral therapies
(ARV). ARV effectiveness then determines the trajec-
tory of clinical indices known to have prognostic sig-
niﬁcance (CD4, viral load), which are used to predict
the likelihood of death. The simulation only represents
those mutations that have been shown to potentially
give rise to resistance to antiretroviral drugs, and does
not represent naturally occurring polymorphisms or
mutations that have other clinical implications.
Figure 1 is an inﬂuence diagram that describes how
these constructs are integrated into the model. Resis-
tance to CART and adherence to CART determine the
level of CART effectiveness. Although greater CART
effectiveness will suppress viral load more completely,
it will also increase selection pressures for particular
mutations that could produce resistance to one or
more drugs in the round. Greater CART effectiveness
reduces the rate of viral replication and therefore
decreases opportunities to produce mutations overall,
however, the mutations that do occur are produced in
an environment of high selection pressure because of
the effectiveness of the therapy against wild type virus.
As resistance accrues, the viral replication rate
increases, and this in turn increases the probability that
subsequent mutations will develop. The effectiveness
of CART inﬂuences changes in the viral load and CD4
count and also feeds back to inﬂuence the viral repli-
cation rate and selection pressures.
When there is resistance or intolerance to a particu-
lar regimen, a new regimen is chosen that includes at
least two drugs from the mechanistic category with the
least phenotypic resistance, and one drug from a sepa-
rate category (unless all possible regimens have been
exhausted). When calibrating the model, the starting
regimen was assumed to include a protease inhibitor;
however, the model is able to accommodate any par-
ticular choice for a starting regimen (e.g., including a
non-nucleoside reverse transcriptase inhibitor).
Several additional principles are embedded in the
model consistent with clinical studies of HIV mutation
accumulation [11–19,28–30,33–42]. First, mutations
accrue because of selection pressures. For example, if
the CART round includes NNRTIs but not PIs, there is
a large probability of accruing a mutation that confers
resistance to an NNRTI, but a negligible probability
of accruing a mutation that confers resistance to a PI
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Figure 1 Inﬂuence diagram of computer simulation.The effectiveness of
combination antiretroviral therapy (CART) is determined by genotypic
resistance and adherence with prescribed medications, processes that are
frequently unobserved. CART effectiveness inﬂuences the clinical trajec-
tory of HIV disease, and consequently impacts survival.
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(Fig. 2). Second, the rate at which an adherent
individual accrues mutations depends on the number
of drugs in the CART regimen to which HIV is sus-
ceptible, because reduced susceptibility permits greater
viral replication under conditions of active selection
pressure. Third, the rate of accruing mutations in
response to active selection pressures is never zero,
even if the round includes three or more drugs to
which there is complete susceptibility of HIV and
therefore maximum suppression of viral replication.
Fourth, each mutation may give rise to resistance to
more than one drug in a particular CART regimen
(cross-resistance), and the likelihood of cross-
resistance is assumed to be heterogeneous across drug
classes (Table 1).
The architecture of this simulation captures the
interdependence of adherence and mutation accumu-
lation that has been observed clinically (higher muta-
tion accumulation at partial levels of adherence, and
lower mutation accumulation at very high or very low
levels of adherence) [19,31]. The model also considers
antiretroviral regimen history because mutations are
assumed to be archived. Therefore, once a regimen has
incurred resistance, it loses its effectiveness perma-
nently. Similarly, if a patient is intolerant to a regimen,
this intolerance is assumed to be permanent.
Because of this design, the development of this
model depends on both measured and unmeasured
parameters. For example, although viral load, CD4
count and resistance patterns are measured, actual
viral replication rates and mutation rates are not.
Measured Parameters
Mortality. Mortality risk for HIV-dependent causes
was assumed to potentially vary with age, sex, race,
risk behavior (injection drug use versus non-injection
drug use), CD4, and viral load, whereas mortality risk
for non-HIV dependent causes was assumed to poten-
tially vary with age, sex, race, and risk behavior. We
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Figure 2 State transition diagram of computer simulation. A new mutation may arise during any time period, and is more likely with greater viral
replication or selection pressures. Each mutation may or may not confer resistance to one or more drugs in the regimen.When there is resistance to all
drugs in the regimen, the simulation will substitute a new regimen unless all possible regimens have been exhausted because of intolerance or resistance.
In this example, the combination antiretroviral therapy regimen is assumed to be comprised of three drugs.
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investigated whether these relationships were clinically
and statistically signiﬁcant by analyzing deaths in a
large multicenter observational study of HIV patients
in the United States, in which cause of death (HIV-
dependent versus non-HIV dependent) was a prespeci-
ﬁed and prospectively collected outcome measure.
These analyses employed Cox Proportional Hazard
models with time dependent covariates, and are
described in further detail elsewhere [21].
Viral load. Our model assumes that the viral load for
each patient has a “set-point” that reﬂects the particu-
lar dynamics between the virulence of the HIV strain
and the activity of the immune system. In the current
analyses, we assume that the viral load before starting
CART reﬂects this “set-point.” Therefore, the current
analyses will not apply to primary HIV infection,
which is characterized by very high viral loads that are
transient. The model assumes that the viral load
decreases after CART is started and that the extent of
the decrease varies with the number of drugs in the
CART round to which there is susceptibility and with
the degree to which the patient adheres to the CART
round (Table 1). If mutations accrue and resistance
develops, the viral load will start to increase and move
toward its set-point. Similarly, if a patient stops taking
one or more drugs, the viral load will start to move
toward its set-point, with the speed of movement
depending on the number of drugs and doses missed. In
accord with clinical data, the viral load will generally
decrease by a larger amount if it is higher to begin with,
and this relationship is instantiated in the model [29].
CD4 count. The CD4 count plays a crucial role in
determining the risk of HIV-related mortality, and
therefore estimating its trajectory is essential for pre-
dicting this mortality risk over long time periods. Pub-
lished data before widespread adoption of CART
suggest that the CD4 count declines at a rate inversely
proportional to the viral load [43]. Nevertheless, pub-
lished data describing this trajectory in the CART era
are scarce and limited by short follow-up times, and do
not suggest that a similar relationship holds. Each new
therapy round typically produces an ascent in the CD4
trajectory, which is followed by a descent as the
therapy becomes less effective. On initiation of a new
and more effective therapy round, the CD4 count
again increases until that round becomes ineffective.
For this reason, each completed therapy round is typi-
cally associated with a valley (when it is started) and a
peak (before its effectiveness starts to wane). To
approximate these dynamics, we modeled CD4 count
trajectories as consisting of two separate components:
1) a temporary valley-to-peak change, which lasts only
as long as a particular CART round is actively sup-
pressing viral replication, and 2) a permanent valley-
to-valley change, which persists independently of the
activity of any particular CART round (Table 1).
Unmeasured Parameters
Resistance mutations. We varied the probability that a
new mutation would occur during a time cycle under
circumstances that were most unlikely for inducing
mutations (perfect adherence, and no baseline resis-
tance). The simulation is speciﬁed so that this single
parameter is then used as the basis for calculating
the probability of developing new mutations in a
wide variety of less favorable but more prevalent
circumstances.
Adherence. We deﬁned adherence as the probability
that a patient will take doses of a particular drug as
directed at any particular time, irrespective of the
reason for which doses may be missed (“pill fatigue,”
side effects, life-threatening toxicity, etc.). Our model
allows individual variation in adherence from time
cycle to time cycle by adding a random variation com-
ponent to a baseline adherence parameter that reﬂects
an individual’s overall propensity toward adherence.
The random variation component is redrawn every
time a new CART round is selected. Adherence is
considered “unmeasured” because although pharmacy
reﬁll databases allow estimation of adherence over
time horizons of one or more months, adherence is
Table 1 Parameters in simulation
Parameter Value Reference
Log decrement in viral load with combination therapy*
Baseline log viral load <3.5 1.07 [21]
Baseline log viral load 3.5–4.5 1.96 [21]
Baseline log viral load 4.5–5.5 2.86 [21]
Baseline log viral load >5.5 3.75 [21]
CD4 change with combination therapy, valley to peak
Round 1 164–208† [21]
Round 2 95–139† [21]
Round 3 0–119† [21]
CD4 change with combination therapy, valley to valley
Round 1 61 [21]
Round 2 -27 [21]
Round 3 -13 to -73‡ [21]
CD4 change without combination therapy (annual)
Baseline log viral load <3.5 -22 [43]
Baseline log viral load 3.5–4.5 -55 [43]
Baseline log viral load 4.5–5.5 -89 [43]
Baseline log viral load >5.5 -122 [43]
Probability of cross-resistance§
NRTI 0.28 [51]
PI 0.43 [51]
NNRTI 0.9 [51]
Probability mutation confers
drug resistance
0.5 [11–19,28–30,33–42]
Mutation rate increase with
new drug resistance (multiple)
3.16 [11–19,28–30,33–42]
*Assumes complete adherence and no resistance.
†Depending on viral load and therapy round. Range is lowered by poor adherence.
‡Depending on therapy round.
§Probability that mutation conferring resistance to one drug also confers resistance to
another drug in same category.
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generally not observed over the smaller time scales that
may be represented in simulations [44–47].
Estimation of Unmeasured Parameters
To test whether the model was calibrated adequately,
we previously compared Kaplan Meier curves of pre-
dicted clinical outcomes (time to treatment failure and
survival) based on simulation estimates with observed
clinical outcomes in a large patient cohort. We per-
formed separate analyses for separate rounds of anti-
retroviral therapy (ﬁrst, second, and third), where a
new therapy round was deﬁned as any change in two
or more antiretroviral drugs. The only variables in
the model that we adjusted during calibration were the
unobserved parameters that we wished to estimate (the
mutation rate in the absence of genotypic resistance,
and the proportion of missed medication doses).
During our initial calibration (April through October,
2003), parameters were adjusted based on visual
inspection of the Kaplan Meier curves; subsequently,
an optimization procedure based on minimizing the
sum of absolute differences was used to verify the
accuracy of these values. The results of this calibration
are reported in detail elsewhere [21].
Comparing Estimated Values to Subsequent
Published Reports
We compared the assigned values for the unobserved
variables with the range of observed values in pub-
lished reports as an additional test of the model’s valid-
ity, as well as to address the larger question of whether
clinical models can be used to estimate the plausible
range of biological parameters that are infrequently
observed or measured. Assigned values were compared
with the pooled 95% Conﬁdence from published
reports using the random effects method of der Simo-
nian and Laird [48–50].
To identify articles reporting mutation rates, we
searched MEDLINE from 1996 onwards (encompass-
ing the entire era of CART). Articles were identiﬁed if
they 1) were indexed by one of the following: text-
words mutation, genotype, resistance or subject head-
ings mutation; genotype; drug resistance, multiple;
drug resistance, viral; drug resistance, microbial; drug
resistance, multiple, viral; drug resistance; 2) were also
indexed by one of the following: text words AIDS,
HAART, CART, or subject headings HIV; Acquired
Immunodeﬁciency Syndrome; Antiretroviral therapy,
highly active; 3) permitted estimation of a mutation
rate either from measurements of mutation prevalence
at two separate times (non-naive patients) or a single
measurement of mutation prevalence after starting
therapy (naive patients); and 4) did not involve
“salvage” therapy (a second round of combination
therapy, after the failure of a ﬁrst round). Articles were
also identiﬁed if they were otherwise known to the
authors or to experts in the ﬁeld, and met conditions
(3) and (4). We assumed that individuals with unde-
tectable viral loads had no new mutations [19] and
that individuals with new genotypic resistance each
had one new mutation, if this number was not other-
wise reported. Because our calibration focused on
individuals who were initially antiretroviral naive, we
separately analyzed the subgroup of studies that exclu-
sively enrolled antiretroviral naive populations.
To identify articles reporting the proportion of
medication doses that were taken as directed, we again
searched MEDLINE starting with 1996. Articles were
identiﬁed if they 1) were indexed by text words adher-
ence, compliance or subject heading compliance; 2)
were indexed by text words HAART, CART, or subject
heading antiretroviral therapy, highly active; 3) were
indexed by text word AIDS or subject headings HIV or
Acquired Immunodeﬁciency Syndrome; and 4) permit-
ted the estimation of the proportion of antiretroviral
medication doses taken as directed (such as through
pharmacy reﬁll records, unanticipated pill counts, or
directly observed therapy). We did not include esti-
mates based exclusively on self-report because of the
inherent imprecision.
Results
Our simulation produced clinically plausible outcomes
for individual patients. Figure 3 shows the trajectories
of CD4 count and viral load of a typical simulated
patient, with superimposed displays of important
events that inﬂuence the effectiveness of therapy.
Changes in regimens occur because of either accumu-
lation of phenotypic resistance or because of difﬁculty
adhering to prescribed antiretroviral medications.
After all regimens are exhausted, the CD4 count
declines steadily after which this hypothetical indi-
vidual dies of a HIV-related cause. Simulated individu-
als also may die of non-HIV related causes, and this is
more likely for individuals who do not fail therapy
and/or have higher CD4 counts.
While calibrating the simulation, we estimated
values for two parameters: the rate of accumulating
resistance mutations, and the likelihood of adherence
with antiretroviral therapies.
Resistance Mutations
We ﬁrst compare our imputed estimate to results for
the studies that were available at the time of calibra-
tion, which usually did not focus exclusively on an
antiretroviral naive population, and were often rela-
tively small. Then, we compare our estimate to results
for the studies that were available after the time of
estimation, which did focus on an antiretroviral naive
population, and were commonly larger.
We estimated that individuals starting their ﬁrst
CART round would accrue new mutations in the
reverse transcriptase and protease genes at a combined
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rate of 0.014 per month during the ﬁrst year based on
our calibration of the model. Nine studies were pub-
lished before this calibration (Table 2). Only three
involved antiretroviral naive populations exclusively,
and the majority involved fewer than 100 individuals.
The pooled results from these studies yielded a 95%
conﬁdence interval (CI) extending from 0.014 muta-
tions per month to 0.039 mutations per month, which
was too wide to permit an inference with a satisfactory
degree of certainty. Pooled results from the studies that
enrolled samples more similar to the target population
(exclusively antiretroviral naive patients) yielded an
even wider 95% CI from 0.001 mutations per month
to 0.029 mutations per month, extending well over
one order of magnitude.
An additional 11 studies were published after
our simulation was calibrated (Table 2). All of them
focused on antiretroviral-naive patients exclusively,
and all but two enrolled at least 100 patients. When
these studies were incorporated into our quantitative
summary, the 95% CI for the mutation rate became
dramatically narrower, decreasing to between 0.017
and 0.021 mutations per month. When we restricted
pooling to those studies that exclusively involved anti-
retroviral naïve patients (more closely resembling our
target population), the 95% conﬁdence remained
narrow, varying from 0.013 mutations per month to
0.017 mutations per month. This range closely brack-
eted our imputed estimate obtained during calibra-
tion (0.014 mutations per month) Furthermore, our
imputed value was identical to the result from the
largest study that enrolled similar patients.
Adherence
During our calibration of the simulation, we estimated
that individuals would have a baseline probability of
adhering to 75% of antiretroviral medication doses as
prescribed. Seven studies were published before our
calibration with results ranging from 45% to 91%
(Table 3). Their pooled 95% CI (65–77%) was reason-
ably narrow and contained our imputed estimate.
An additional four studies were published after our
calibration (Table 3). When these results were incor-
porated into the pooled estimate, the 95% CI did
not change appreciably (62–76%), and continued to
contain our imputed estimate.
Discussion
Our HIV simulation was constructed during the
current treatment era of highly active antiretroviral
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Figure 3 Example of CD4 (ﬁlled diamond) and viral load (clear box) trajectories of one simulated patient.This patient started the simulation with a CD4
count of 500 and a viral load at a “set-point” of 100,000. After starting combination antiretroviral therapy (CART), the CD4 count rose and the viral load
declined. As time passed, the patient developed genotypic and phenotypic resistance to all possible CART rounds,mitigating the favorable effects of CART
on CD4 count and viral load. Finally, the patient developed resistance to all possible rounds. Changes in regimens occur because of either accumulation
of phenotypic resistance or because of difﬁculty adhering to prescribed antiretroviral medications. Not every mutation will lead to an adverse change in
CD4 or viral load immediately, but after several mutations phenotypic resistance is likely to accumulate and consequently there will be a need to change
regimens. Later rounds are less effective at suppressing viral load and elevating CD4 count compared with earlier rounds, mirroring widely observed
patterns.After all regimens are exhausted, the CD4 count declines steadily after which this hypothetical individual dies of a HIV-related cause. Simulated
individuals also may die of non-HIV related causes, and this is more likely for individuals who do not fail therapy and/or have higher CD4 counts.
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treatments, and therefore it was designed “from the
ground up” to consider the most important processes
that limit the effectiveness and duration of this treat-
ment: genotypic resistance and nonadherence to
therapy. One difﬁculty we encountered while devel-
oping our simulation is that genotypic mutations are
not measured at regular intervals as part of routine
clinical care. For this reason, these parameters are
often unobserved, and it was difﬁcult to derive esti-
mates for their values from clinical data sources.
Soon after we estimated values for these parameters
during model calibration, several large studies were
published which prospectively measured the rate of
accumulating resistance mutations. The validity of
the model is enhanced by the observation that that
our estimated values were well within the conﬁdence
limits of pooled analyses of these studies. Indeed, the
results from the largest and most comparable popu-
lations (antiretroviral naive individuals) were only
available after we calibrated the simulation, yet
offered the strongest evidence that its estimates were
accurate.
Investigators who have used models to answer
pharmacoeconomic and other questions in health care
Table 2 Estimates for mutation rate published before versus after imputation of the corresponding model parameter
Author Year N
Median follow-up
(months)
Antiretroviral
naive exclusively?
Mutation incidence
(per month)
Studies published before model calibration
Race et al. [11] 1998 25 11 No 0.018
Michelet et al. [12] 1999 16 11 No 0.017
Gulick et al. [13] 2000 33 36 No 0.014
Maguire et al. [52] 2000 105 9 Yes 0.020
Pellegrin et al. [53] 2002 48 16 No 0.022
Walmsley et al. [54] 2002 653 11 Yes 0.003
Von Vaerenbergh et al. [55] 2002 25 36 Yes 0.022
Bangsberg et al. [19] 2003 148 6 No 0.073
Squires et al. [14] 2003 552 6 No 0.049
Cumulative 95% conﬁdence interval, all studies pooled 0.014–0.039
Cumulative 95% conﬁdence interval, antiretroviral naive studies pooled 0.001–0.029
Studies published after model calibration
Weidle et al. [56] 2003 399 6 Yes 0.025
Vergne et al. [57] 2003 66 18 Yes 0.012
Martinez-Picado et al. [58] 2003 99 11 Yes 0.018
Ferrer et al. [59] 2003 100 11 Yes 0.011
Demeter et al. [60] 2004 517 6 Yes 0.015
Gallant et al. [61] 2004 600 33 Yes 0.005
Kemp et al. [28] 2004 653 15 Yes 0.018
Bocket et al. [29] 2004 165 10 Yes 0.012
MacManus et al. [30] 2004 649 11 Yes 0.010
Harrigan et al. [31] 2005 1191 12 Yes 0.014
Laurent et al. [62] 2005 176 30 Yes 0.0035
Cumulative 95% conﬁdence interval, all studies pooled 0.017–0.021
Cumulative 95% conﬁdence interval, antiretroviral naive studies pooled 0.012–0.015
The target population consists of individuals who were antiretroviral naïve before the initiation of therapy.
Table 3 Estimates for medication adherence published before versus after imputation of the corresponding model parameter.
Nonadherence is deﬁned as the proportion of doses taken as prescribed
Author Year N
Median follow-up
(months)
Proportion of doses
taken as directed (%)
Studies published before model calibration
Haubrich et al. [44] 1999 173 1 91
Paterson et al. [45] 2000 99 6 75
Howard et al. [46] 2002 161 1 45–64
Arnsten et al. [47] 2002 85 5 53
Golin et al. [63] 2002 140 11 71
Van Wijngaerden et al. [64] 2002 43 3 86
Bangsberg et al. [19] 2003 148 12 65
Cumulative 95% conﬁdence interval 65–77
Studies published after model calibration
Halkitis et al. [65] 2003 68 1 82–91
Remien et al. [66] 2005 109 2 39
Rathbun et al. [67] 2005 17 6 51
Harrigan et al. [31] 2005 1130 12 84*
Cumulative 95% conﬁdence interval 62–76
*Approximated based on adherence that was reported in discrete strata.
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commonly need to estimate the value of unobserved
parameters by calibrating model output to separate,
observed outcomes of interest. Goldie et al. have devel-
oped a natural history model of cervical cancer to
estimate the cost-effectiveness of various screening
strategies for human papilloma virus infection, in
which they estimated the likelihood of transitioning
from premalignant to malignant lesions based on the
observed incidence of these lesions [23–25]. Fryback
et al. has developed a natural history model of breast
cancer, in which they estimated the proportion of
breast cancer precursors that are unlikely to transition
from premalignant to malignant lesions based on the
incidence of malignant lesions [26]. Although the
current simulation does not involve cancer, it involves
analogous clinical constructs in the natural history of
HIV. An unobserved event (mutation rate) gives rise to
an observed event (failure of antiretroviral therapy),
and inferences about the unobserved event are made
based on characterizations of the observed event. Fur-
thermore, the likelihood of antiretroviral failure is also
dependent on a partially observed parameter, the com-
pliance. Our results provide support to the assertion
that it is feasible to estimate the values of selected
simulation parameters as long as there are substantial
additional checks on the simulation’s calibration and
validity.
This natural experiment occurred because of a con-
ﬂuence of circumstances. Assays for genotypic muta-
tions did not have great clinical utility until the advent
of the current CART regimens, which have only been
in use for less than a decade. Even after the potential
utility of these tests were clear, their great expense
made frequent and prospectively scheduled testing
prohibitively expensive, thereby discouraging their
systematic use. For this reason, much of the initial
mutation accumulation data was on small groups of
patients, and often was retrospective. This led to sub-
stantial time lag between when the clinical importance
of modeling resistance became apparent, and when
large prospective data sources became available.
Our study has several limitations. Some of the pub-
lished reports used outcome metrics that were not
identical to those used in our simulation. The simula-
tion does not yet discriminate between individual
drugs within any one antiretroviral category, and does
not discriminate between individual mutations that
may confer resistance to any one antiretroviral drug
category, and therefore more in depth validation of
estimated parameter results is not possible. Finally,
although we demonstrate that it is possible to use
imputation to produce accurate parameter estimates,
the generalizability of this ﬁnding is unclear, because it
would not be expected to apply to models with great
structural or parameter uncertainty.
In conclusion, we have created a computer simula-
tion of HIV disease in the era of CART that represents
the unobserved processes that are the main determi-
nants of treatment failure: antiretroviral adherence
and the accrual of mutations that confer genotypic
resistance. While calibrating the simulation, we esti-
mated values for these variables. These estimates not
only were well within the range of clinical observa-
tions, but anticipated with accuracy clinical results
that were not yet available. It may be feasible to use
models to estimate the values of unobserved biological
parameters.
This study was supported by Grant K23 AA14483-01 from
the National Institute of Alcohol Abuse and Alcoholism.
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